Loss of B Cell Tolerance in Primary Immunodeficiencies
原发性免疫缺陷导致 B 细胞耐受性丧失
基本信息
- 批准号:6847373
- 负责人:
- 金额:$ 21.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-01 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Antibodies are generated during early B cell development by random joining of immunoglobulin (Ig) gene segments. Ig gene recombination can result in the assembly of self-reactive antibodies or B cell receptors (BCR). B cells that develop self-reactive receptors can be silenced by one of three mechanisms: deletion, anergy; and receptor editing. Whereas deletion and anergy ultimately eliminate self-reactive B cells, receptor editing rescues them by replacing autoreactive antibodies. We analyzed how B cell tolerance was established in humans by following the evolution of autoantibody-producing B cells during B cell development. We found that 55-75% of early B cell precursors expressed self-reactive antibodies and that autoantibodyproducing
B cells in healthy donors were removed from the population at two discrete checkpoints. The
mechanisms that prevail in silencing these autoreactive B cells remain to be characterized, and little is known about the effect of antibody specificity and BCR signaling in regulating the balance between deletion, anergy, and receptor editing. However, defects in BCR signaling have been reported in B cells from patients with systemic lupus erythematosus and common variable immunodeficiency (CVID) who frequently develop autoimmunity suggesting that BCR signaling may play a role in counterselecting self-reactive B cells.
The long range goal of the proposed research is to elucidate the role of BCR in the regulation of B cell tolerance by analyzing primary immunodeficient patient B cells with altered BCR signaling. The working hypothesis is that BCR signaling is essential in establishing B cell tolerance and when it is affected, autoreactive B cells are not silenced and can migrate to the periphery. The first aim of the project will consist of cloning antibodies from single B cells from the blood of X-linked agammaglobulinemia patients and determine whether modified threshold of BCR signaling in btk gene-deficient B cells impacts B cell tolerance mechanisms. The second part of the project will analyze how BCR co-receptors such as CD40 influence the establishment and the maintenance of B cell tolerance in hyper-IgM patients. The third part of the project will
study B cell tolerance in CVID patients. These studies have significant implications for understanding how self-reactive B cells may be produced with or without maintaining self-tolerance.
通过免疫球蛋白(IG)基因段的随机连接在早期B细胞发育过程中产生抗体。 Ig基因重组会导致自反应性抗体或B细胞受体(BCR)组装。产生自我反应受体的B细胞可以通过三种机制之一来保持沉默:缺失,无反应;和受体编辑。而删除和消极最终消除了自反应的B细胞,而受体编辑通过替换自动反应性抗体来挽救它们。我们通过遵循B细胞发育过程中产生自身抗体的B细胞的进化来分析在人类中如何建立B细胞的耐受性。我们发现55-75%的早期B细胞前体表达了自反应性抗体,并且自身抗体生产
在两个离散检查点中,将健康供体中的B细胞从人群中删除。这
沉默这些自动反应性B细胞的机制仍有待表征,并且对抗体特异性和BCR信号传导在调节缺失,不良和受体编辑之间的平衡的影响知之甚少。然而,已经报道了来自全身性红斑狼疮患者的B细胞中BCR信号传导的缺陷和常见的可变免疫缺陷(CVID),这些免疫缺陷(CVID)经常发展自身免疫性,这表明BCR信号可能在反反应性B细胞中发挥作用。
拟议研究的远距离目标是通过分析因BCR信号改变的原发性免疫缺陷患者B细胞来阐明BCR在调节B细胞耐受性中的作用。工作假设是,BCR信号对于建立B细胞的耐受性至关重要,并且在受影响时,自动反应性B细胞不会沉默,并且可以迁移到周围。该项目的第一个目的是由来自X连锁Agammagloblobloblobloblobloinemia患者血液中的单个B细胞的克隆抗体组成,并确定BTK基因缺陷型B细胞中BCR信号传导的修饰阈值是否会影响B细胞耐受机制。该项目的第二部分将分析BCR共受体(例如CD40)如何影响Hyper-IGM患者B细胞耐受性的建立和维持。该项目的第三部分将
研究CVID患者的B细胞耐受性。这些研究对了解如何在不保持自我耐受的情况下如何产生自我反应性B细胞具有重要意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Eric Meffre的其他基金
Elucidating the immunology of autoantibody formation and function in COVID-19
阐明 COVID-19 中自身抗体形成和功能的免疫学
- 批准号:1063970710639707
- 财政年份:2023
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
SYK and ZAP70 kinases in lymphocyte selection
SYK 和 ZAP70 激酶在淋巴细胞选择中的作用
- 批准号:1046721510467215
- 财政年份:2022
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
SYK and ZAP70 kinases in lymphocyte selection
SYK 和 ZAP70 激酶在淋巴细胞选择中的作用
- 批准号:1055788210557882
- 财政年份:2022
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Impact of regulatory T cells on human peripheral B cell tolerance
调节性 T 细胞对人外周 B 细胞耐受的影响
- 批准号:84242168424216
- 财政年份:2012
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Impact of regulatory T cells on human peripheral B cell tolerance
调节性 T 细胞对人外周 B 细胞耐受的影响
- 批准号:83025788302578
- 财政年份:2012
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Loss of B cell tolerance in rheumatoid arthritis
类风湿性关节炎 B 细胞耐受性丧失
- 批准号:80917618091761
- 财政年份:2010
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Autoreactive B Cell Development in Autoimmune Disease
自身免疫性疾病中自身反应性 B 细胞的发育
- 批准号:76876827687682
- 财政年份:2009
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Loss of B Cell Tolerance in Rheumatoid Arthritis
类风湿性关节炎 B 细胞耐受性丧失
- 批准号:89687998968799
- 财政年份:2006
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Loss of B Cell Tolerance in Rheumatoid Arthritis
类风湿性关节炎 B 细胞耐受性丧失
- 批准号:88110798811079
- 财政年份:2006
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Loss of B Cell Tolerance in Rheumatoid Arthritis
类风湿性关节炎 B 细胞耐受性丧失
- 批准号:85864598586459
- 财政年份:2006
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
相似国自然基金
WDR68通过PRC1复合体增强H3K27ac修饰促进急性B淋巴细胞白血病发生的机制及预后价值研究
- 批准号:82302600
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
阑尾B淋巴细胞对溃疡性结肠炎发生发展的始动和促进作用研究
- 批准号:82370537
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
Hippo信号通路调控B淋巴细胞分化在狼疮肾炎中的作用与机制研究
- 批准号:82302023
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
非典型蛋白激酶C在B淋巴细胞介导免疫应答中的作用机制研究
- 批准号:32300740
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ISG15+ B淋巴细胞通过与PD-1+CXCR5−CD4+ Th-CXCL13 T细胞相互作用介导三级淋巴结构的形成和成熟以促进复发转移鼻咽癌免疫联合抗血管治疗响应的作用及机制研究
- 批准号:82373258
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
相似海外基金
Enhancing Killer B Lymphocyte Function as a Treatment for Allergic Asthma
增强杀伤 B 淋巴细胞功能治疗过敏性哮喘
- 批准号:84895598489559
- 财政年份:2013
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Enhancing Killer B Lymphocyte Function as a Treatment for Allergic Asthma
增强杀伤 B 淋巴细胞功能治疗过敏性哮喘
- 批准号:87404678740467
- 财政年份:2013
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Role of Macrophage Costimulatory Molecules in Polymicrobial Sepsis
巨噬细胞共刺激分子在多种微生物脓毒症中的作用
- 批准号:72118177211817
- 财政年份:2007
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Role of Macrophage Costimualtory Molecules in Polymicrobial Sepsis
巨噬细胞共刺激分子在多种微生物脓毒症中的作用
- 批准号:73390197339019
- 财政年份:2007
- 资助金额:$ 21.45万$ 21.45万
- 项目类别:
Role of Macrophage Costimualtory Molecules in Polymicrobial Sepsis
巨噬细胞共刺激分子在多种微生物脓毒症中的作用
- 批准号:77417317741731
- 财政年份:2007
- 资助金额:$ 21.45万$ 21.45万
- 项目类别: